Furthermore, recognizing aPL-stroke may benefit in preventing direct oral anticoagulant (DOAC) misuse in underdiagnosed aPL-stroke patients, considering recent reports of DOAC-related harm in antiphospholipid syndrome (APS)7–9. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.